Compare Biogen Inc (BIIB) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs KeyCorp — how do they compare? Biogen Inc trades at $193.83 (market cap $28.34B), while KeyCorp trades at $23.45 (market cap $25.15B). The key difference: Biogen Inc and KeyCorp are close in size by market cap, and KeyCorp pays a 3.52% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KEY | |
|---|---|---|
Market Cap | $28.34B | $25.15B |
Sector | Health | Financials |
52-Week High | $216.63 | $23.43 |
52-Week Low | $122.68 | $16.78 |
Enterprise Value | $30.62B | — |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
KeyCorp (KEY) trades at $23.22, down 0.34% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamental recovery with Q1 2026 EPS beating expectations at $0.44 and a net income margin of 26.05% for 2025. Analyst consensus is heavily bullish with a $29.32 price target, and recent news highlights partnerships and a new $3 billion buyback program.
The outlook for KEY is positive, driven by earnings beats, robust capital returns, and improving profitability. Risks include volatile cash flows and macroeconomic sensitivity, but institutional support and a low P/E of 14.25 suggest undervaluation, offering potential upside for investors seeking regional bank exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
